Instrument Inactif

Communiqués Wilex AG Deutsche Boerse AG

Actions

DE0006614720

Recherche biotechnologique et médicale

Cours en clôture Deutsche Boerse AG Autres places de cotation
- ^EUR	-

15/07	Heidelberg Pharma AG publie ses résultats pour le premier semestre clos le 31 mai 2026	CI
23/06	Heidelberg Pharma AG approuve l'élection de M. Jack Yefei Ling au sein de son conseil de surveillance	CI

Communiqués

15/07	SIMRIS GROUP AB APPOINTS ADC EXPERT PROFESSOR ANDREAS PAHL AS CHIEF EXECUTIVE OFFICER OF ITS SUBSIDIARY SIMRIS BIOLOGICS GMBH	AQ
15/07	Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business	EQ
23/06	Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026	EQ
13/05	Heidelberg Pharma : Explanations on the resolutionless agenda item 1 (HDP ExplanationItem1)	PU
13/05	Heidelberg Pharma : CV of the proposed Supervisory Board candidate (202605 CV AR 2026 engl)	PU
13/05	Heidelberg Pharma : Articles of Association (20260121 HeidelbergPharma ArticlesAssociation)	PU
13/05	Heidelberg Pharma : Explanation of shareholders' rights (HDP explanations of the rights of shareholders copy 2)	PU
13/05	Heidelberg Pharma : Power of attorney to the proxies of the company (HDP power of attorney to proxies)	PU
13/05	Heidelberg Pharma : Proxy to a third person (HDP power of attorney to third person)	PU
13/05	Heidelberg Pharma : Revocation of proxy (HDP revocation of proxy)	PU
13/05	Heidelberg Pharma : Information on data protection (HDP Data protection information for shareholders copy 2)	PU
13/05	Heidelberg Pharma : Agenda and convening of the general meeting (EN Einberufung und Tagesordnung)	PU
13/05	Heidelberg Pharma : Information pursuant to § 125 AktG and Table 3 Blocks A to F Implementing Regulation EU 2018/1212) (HDP Informationen nach 125 AktG und Tabelle 3 Blocke A bis F Durchfuhrungsverordnung EU 2018 1212 engl)	PU
29/04	Heidelberg Pharma : Interim statement on the first three months of 2026	PU
29/04	Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026	EQ
17/04	Heidelberg Pharma Announces Change in Executive Board	EQ
09/04	Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	EQ
04/04	Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026	EQ
26/03	Heidelberg Pharma : Präsentation Bilanzpressekonferenz 2026	PU
26/03	Heidelberg Pharma : Presentation Analyst and Press Conference 2026	PU
26/03	Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026	EQ
18/03	Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China	EQ
10/03	Heidelberg Pharma AG: Dr. Birgit Kudlek, sell	EQ
10/03	Heidelberg Pharma AG: Dr. Birgit Kudlek, sell	EQ
09/03	PR: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital	PU